Drug Profile
Research programme: BACE-1 inhibitors - GlaxoSmithKline
Alternative Names: GSK 188909Latest Information Update: 21 Apr 2011
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 31 Dec 2010 No development reported - Preclinical for Alzheimer's disease in United Kingdom (PO)